Antineoplastics
1
Reactions 1510, p10 - 19 Jul 2014 S Antineoplastics Therapy-related acute myeloid leukemia: case report A 27-year-old woman developed therapy-related acute myeloid leukemia after treatment with cyclophosphamide, dactinomycin, etoposide, methotrexate and vincristine. The woman had a history of persistent complete hydatidiform mole, which had been successfully treated earlier. She presented with fatigue, sore throat and petechiae which had been present for a few weeks. Her prior treatment included a single cycle of methotrexate [dosage and route not stated]. Because of a further increase in human chorionic gonadotropin, methotrexate cycle was followed by, nine biweekly cycles of the EMA/CO regimen, which consisted of etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine [dosages and routes not stated]. Blood work at this time showed hemoglobin 10.9 g/dL, WBC 41.4 × 10 9 /L, platelets 15 × 10 9 /L and 60% blasts. The bone marrow was packed with immature myeloid cells. Cytogenetic analysis revealed a diagnosis of therapy-related acute myeloid leukemia (t-AML) [duration of treatment to reaction onset not clearly stated; outcome not stated]. Author comment: "A diagnosis of therapy-related acute myeloid leukemia (t-AML) was established." "EMA/CO carries a high risk of about 0.7% for future t-AML" Rashidi A, et al. After the treated mole. Blood 123: 2757, No. 18, 01 May 2014. Available from: URL: http://doi.org/10.1182/blood-2014-01-552406 - USA 803105875 1 Reactions 19 Jul 2014 No. 1510 0114-9954/14/1510-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1510, p10 - 19 Jul 2014
SAntineoplastics
Therapy-related acute myeloid leukemia: casereport
A 27-year-old woman developed therapy-related acutemyeloid leukemia after treatment with cyclophosphamide,dactinomycin, etoposide, methotrexate and vincristine.
The woman had a history of persistent completehydatidiform mole, which had been successfully treatedearlier. She presented with fatigue, sore throat and petechiaewhich had been present for a few weeks. Her prior treatmentincluded a single cycle of methotrexate [dosage and route notstated]. Because of a further increase in human chorionicgonadotropin, methotrexate cycle was followed by, ninebiweekly cycles of the EMA/CO regimen, which consisted ofetoposide, methotrexate, dactinomycin, cyclophosphamide,and vincristine [dosages and routes not stated]. Blood work atthis time showed hemoglobin 10.9 g/dL, WBC 41.4 × 109/L,platelets 15 × 109/L and 60% blasts. The bone marrow waspacked with immature myeloid cells. Cytogenetic analysisrevealed a diagnosis of therapy-related acute myeloidleukemia (t-AML) [duration of treatment to reaction onset notclearly stated; outcome not stated].
Author comment: "A diagnosis of therapy-related acutemyeloid leukemia (t-AML) was established." "EMA/CO carries ahigh risk of about 0.7% for future t-AML"Rashidi A, et al. After the treated mole. Blood 123: 2757, No. 18, 01 May 2014.Available from: URL: http://doi.org/10.1182/blood-2014-01-552406 -USA 803105875
1
Reactions 19 Jul 2014 No. 15100114-9954/14/1510-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
